Menu
Menu
Precision medicine stands at the edge of a data-driven revolution, with multimodal real-world data driving the next wave of drug development.
Our expertise in data science and AI-powered analytics helps you address translational hurdles, build global evidence, and optimize patient stratification to improve outcomes across borders.
Translational Research
Real-World Insights
Biomarker Signature
“Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, and thus contributing to the improvement of patient outcomes across the African continent.
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations in patients with relapsed or refractory DLBCL that correlate with clinical response to ADCT-402. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment.”
“Using AI and machine learning, we can integrate multiple forms of data, generating insights that inform prognosis and therapeutic response at the individual patient level. This aligns with our focus on developing personalized cancer treatments and elevating precision oncology to a truly multimodal, interconnected health ecosystem.”
“At AstraZeneca, a core component of our AI strategy has been rooted in the deployment of frontier AI solutions across oncology clinical development. Fine tuning and augmenting our models with multimodal data — including our own data and the data that will be generated as part of this collaboration — is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer.”
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
Powered by Bioz
